Cytokines pattern of Multiple Sclerosis patients treated with Apitherapy
|
|
|
- Howard Norman
- 10 years ago
- Views:
Transcription
1 Cytokines pattern of Multiple Sclerosis patients treated with Apitherapy Ahmad G. Hegazi, Khaled Al- Menabbawy, Eman H. Abd El- Rahman and Suzette I. Helal National Research Center, Dokki, Giza, Egypt com and
2 4 rd International Conference and Exhibition on Clinical & Cellular Immunology September September, 2015 Houston, USA Cytokines pattern of Multiple Sclerosis patients treated with Apitherapy
3
4
5
6 It is an Auto Immune Disease which is when the body starts to destroy itself. It is a life-long disease with no cure. In MS, the body attacks and destroys the fatty tissue called myelin that insulates an axon/nerve, and is called demyelination. If damage is severe it can also destroy the nerve/axon itself. MS affects the central nervous system and inflames the white matter in the brain which creates plaques..
7 Definition of Multiple Sclerosis An inflammatory demyelinating disease of the CNS where there is: Dissemination in space Dissemination in time No alternative neurologic disease MS is a clinical diagnosis
8 Multiple Sclerosis Epidemiology The most common progressive neurologic disease of young adults Affects 350,000 persons in the USA Risk Factors: Female sex White race Northern latitude (USA) High socioeconomic status Scandinavian ancestry
9 MULTIPLE SCLEROSIS FEATURES two stages disease: inflammation and neurodegeneration 4,000,000 people affected worldwide Women:men 2:1 Age of disease onset: ys (young adulthood)
10 Neurological impairments: blindness, loss of sensation, lack of coordination, incontinence, paralysis Relapsing-remitting (80%); chronic progressive (10%); benign (10%)
11 Disease Overview: Autoimmunity Peripheral tolerance involves a populations of regulatory T cells which maintain autoreactive T cells in a dormant state in the circulation in adults. P. Martini
12 The autoreactive T cells can be awoken from this state by local or environmental stimuli such as exposure to endogenous or exogenous antigens in the circulation. In MS these cells becomes activated either because of failure of the mechanism of peripheral tolerance or due to priming by antigens.
13
14 MULTIPLE SCLEROSIS FEATURES Once activated autoreactive T cells release a cocktails of cytokines that are important for migration and homing of the cells to the target sites and for initiation of the inflammatory process
15 Disease Overview: Multiple Sclerosis Multiple Sclerosis (MS) is an inflammatory disease of the Central Nervous System (CNS) affecting the brain and spinal cord. Predominantly, it is a disease of the "white matter" tissue. The white matter is made up of nerve fibers which are responsible for transmitting communication signals both internally within the CNS and between the CNS and the nerves supplying rest of the body.
16 Multiple Sclerosis Etiology Possible precipitating factors include Infection Physical injury Emotional stress Excessive fatigue Pregnancy Poor state of health
17 Multiple Sclerosis Etiology and Pathophysiology Myelin can be replaced by glial scar tissue Without myelin, nerve impulses slow down With destruction of axons, impulses are totally blocked Results in permanent loss of nerve function
18
19 Signs & Symptoms : The person with MS can sufferalmost any neurological symptom or sign, including: changes in sensation, muscle weakness, spasm, or difficulty in moving; difficulties with coordination and balance;
20 Signs & Symptoms : problems in speech or swallowing, visual problems, fatigue, pain bladder and bowel difficulties. Cognitive impairment of varying degrees emotional symptoms of depression or unstable mood are also common.
21 Symptoms of MS Fatigue Depression Memory change Pain Spasticity Vertigo Tremor Double Vision/Vision Loss Weakness Dizziness/Unsteadiness Numbness/Tingling Ataxia Euphoria Speech disturbance Bladder/Bowel/Sexual dysfunction
22 Causes Of MS : Most likely MS occurs as a result of some combination of genetic, environmental and infectious factors. Epidemiological studies of MS have provided hints on possible causesforthedisease.
23 Theories try to combine the known data into plausible explanations, butnonehasproveddefinitive. Genetics: Environmental factors: Infections:
24 Genetics Of MS
25 Radiological Findings
26
27
28
29 Magnetic Resonance Imaging in MS Spinal cord Optic nerve Brain
30 Brain Atrophy (Shrinkage) in Untreated MS Images acquired over the course of 7 years from a single person with untreated MS
31 MRI: Spinal Imaging
32
33 Eighty patients known to be with MS, Twenty four males and fifty six females, their ages ranged between years, with a mean of 38.7 ±
34 All cases were subjected to complete clinical and neurological history and examination to confirm the diagnosis.
35 There were 44 cases with quadriparesis, (12 males and 32 female) and 36 cases with paraparesis (12 males and 24 females).
36 All cases were under their regular treatment either by corticosteroids,orinterferon. These cases were divided into two main groups, each group consists of 40 cases (12 males and 28 females),
37 Group I received honey, pollen, royal jelly and propolis and were treated with bee acupuncture 3 times weekly, for 12 months, started gradually by one sting then gradually increase up to 25 stings per session, in addition to their medical treatment
38 while group II remains on their ordinary medical treatment only.
39 Bee acupuncture done by bee stings for regulating the immunesystem in thefollowing points Du 13, 14, Li 11, S6, S9, points for MS Pat Wagner Buttocks Jiagi points forcervical area and lumber area and vision pointsgb2and Li3.
40 All patients were instructed to receive mgvitaminc, 15 mgvit. B1, 3 mgvit. B2, 2mgVit. B6, 5 mgvit. B12,
41 25 mg Folicacid, 3 mg Calciumpantothenate, 15mg Nicotinamide, 20 mg L-Arginine, 20 mg L- Lysine and 3 mcg Biotin/day.
42 Serum samples were obtained from patients with clinically definite MS for estimation of serum levels of immunoglobulin E (Hiranoet al., 1989) using commercially available ELISA kits according to the manufacturers' directions.
43 Serum cytokine levels IFN-γ, interleukin (IL) 1β, IL-4, IL-6, IL-10, tumor necrosis factor alpha (TNFα) were assessed using enzyme inked - immunosorbent assays (Abrams, 1995) using commercially available ELISA kits according to the manufacturers' directions (kits produced by Bender Med System, Vienna, Austria).
44 All these investigations were done at the beginning of the study and by the end of one year of supplementation and bee sting sessions
45
46 Wefound that8patients outof 12 (66.6 %of paraparesiscases), showed some improvement regarding theirdefectsingait, bowelcontrol, constipation andurination,
47 while 12 cases out of 16 cases (75% of quadriparesis cases), showed some mild improvement in their movement in bed, and better improvement in bed sores, sensation, and better motor power, only two cases of them ( 12.5% ) were able to stand for few minutes with support.
48 Symptoms Score Improvement Recorded Every Two Months (1-12):
49 Symptoms Score Improvement Recorded Every Two Months (1-12):
50 Symptoms Score Improvement Recorded Every Two Months (1-12):
51 Symptoms Score Improvement Recorded Every Two Months (1-12):
52 Symptoms Score Improvement Recorded Every Two Months (1-12):
53 Symptoms Score Improvement Recorded Every Two Months (1-12):
54 Symptoms Score Improvement Recorded Every Two Months (1-12):
55 Symptoms Score Improvement Recorded Every Two Months (1-12):
56 Symptoms Score Improvement Recorded Every Two Months (1-12):
57 Symptoms Score Improvement Recorded Every Two Months (1-12):
58 Symptoms Score Improvement Recorded Every Two Months (1-12):
59 Symptoms Score Improvement Recorded Every Two Months (1-12):
60 Symptoms Score Improvement Recorded Every Two Months (1-12):
61 Symptoms Score Improvement Recorded Every Two Months (1-12):
62 Symptoms Score Improvement Recorded Every Two Months (1-12):
63 Symptoms Score Improvement Recorded Every Two Months (1-12):
64 Symptoms Score Improvement Recorded Every Two Months (1-12):
65 Symptoms Score Improvement Recorded Every Two Months (1-12):
66 Symptoms Score Improvement Recorded Every Two Months (1-12):
67 Symptoms Score Improvement Recorded Every Two Months (1-12):
68 Mean levels of IgE of both groups at the start and end of the study
69 Mean levels of (TNF) αof both groups at the start and end of the study
70 Mean levels of (IL) 1βof both groups at the start and end of the study
71 Mean levels of IL-6 of both groups at the start and end of the study
72 Mean levels of (IL 4) of both groups at the start and end of the study
73 Mean levels of IL-10 of both groups at the start and end of the study
74
75 Although Apitherapy is not a curable therapy in MS, but it can be used to minimize some of the clinical symptoms of MS, and can be included amongprogramsof MS therapy.
76
77 Cytokines pattern of Multiple Sclerosis patients treated with Apitherapy Ahmed G. Hegazi National Research Center, Egypt
78 Cytokines pattern of Multiple Sclerosis patients treated with Apitherapy Ahmed G. Hegazi National Research Center, Egypt
79 Prof. Dr. Ahmed Hegazi Professor of Microbiology and Immunology National Research Center, Dokki, Giza, Egypt President of Egyptian Environmental Society for uses and production of bee products Secretary of Egyptian Society of Apitherapy Secretary General of African Federation of Apiculture Associations Member of Apitherapy Commission, APIMONDIA E mail: [email protected] and [email protected] Tel: and Fax: and GMS:
A Definition of Multiple Sclerosis
English 182 READING PRACTICE by Alyx Meltzer, Spring 2009 Vocabulary Preview (see bolded, underlined words) gait: (n) a particular way of walking transient: (adj) temporary; synonym = transitory remission:
What is Multiple Sclerosis? Gener al information
What is Multiple Sclerosis? Gener al information Kim, diagnosed in 1986 What is MS? Multiple sclerosis (or MS) is a chronic, often disabling disease that attacks the central nervous system (brain and spinal
Muscular Dystrophy and Multiple Sclerosis. ultimately lead to the crippling of the muscular system, there are many differences between these
Battles 1 Becky Battles Instructor s Name English 1013 21 November 2006 Muscular Dystrophy and Multiple Sclerosis Although muscular dystrophy and multiple sclerosis are both progressive diseases that ultimately
Life with MS: Striving for Maximal Independence & Fulfillment
Life with MS: Striving for Maximal Independence & Fulfillment St. Louis, May 7, 2005 Florian P. Thomas, MA, MD, PhD MS Center, Department of Neurology Associate Professor, Saint Louis University Brain
Multiple Sclerosis (MS)
Multiple Sclerosis (MS) Purpose/Goal: Care partners will have an understanding of Multiple Sclerosis and will demonstrate safety and promote independence while providing care to the client with MS. Introduction
http://images.tutorvista.com/content/control5coordination/human5brain.jpeg!! 387
http://images.tutorvista.com/content/control5coordination/human5brain.jpeg!! 387! 388! http://my.fresnounified.org/personal/lygonza/gonzalez/neuron/neuron5synapse%20communication.png!! http://www.urbanchildinstitute.org/sites/all/files/databooks/2011/ch15fg25communication5between5neurons.jpg!!
Trauma Insurance Claims Seminar Invitation
Trauma Insurance Claims Seminar Invitation Introduction Since the development of Trauma Insurance in Australia in the 1980s, the product has evolved at a great pace. Some of the challenges faced by claims
Understanding. Multiple Sclerosis. Tim, diagnosed in 2004.
Understanding Multiple Sclerosis Tim, diagnosed in 2004. What Is Multiple Sclerosis? Multiple sclerosis (MS) is a neurologic disorder that affects the central nervous system (CNS). The CNS includes the
Managing the Symptoms of Multiple Sclerosis. Yolanda Harris, MSN, CRNP-AC CPODD Nurse Practitioner
Managing the Symptoms of Multiple Sclerosis Yolanda Harris, MSN, CRNP-AC CPODD Nurse Practitioner What is Multiple Sclerosis An autoimmune disease that affects the central nervous system (CNS) The immune
CBT IN THE CITY. adjusted to the news of being with MS? April 2013. Experts at your fingertips call now. Check out our new services in you local area
April 2013 Experts at your fingertips call now CBT IN THE CITY Check out our new services in you local area contents. A message from Susie, Information Multiple Sclerosis CBT can make a difference on the
Multiple Sclerosis: What You Need To Know. For Professionals
Multiple Sclerosis: What You Need To Know For Professionals What will I learn today? The Basics: What is MS? Living with MS: A Family Affair We Can Help: The National MS Society What MS Is: MS is thought
Multiple sclerosis (MS)
Multiple sclerosis (MS) Summary Multiple sclerosis (MS) is an incurable disease of the central nervous system that can affect the brain, spinal cord and optic nerves. The effects of MS are varied and unpredictable,
Cerebral palsy can be classified according to the type of abnormal muscle tone or movement, and the distribution of these motor impairments.
The Face of Cerebral Palsy Segment I Discovering Patterns What is Cerebral Palsy? Cerebral palsy (CP) is an umbrella term for a group of non-progressive but often changing motor impairment syndromes, which
MULTIPLE SCLEROSIS. Mary Beth Rensberger, RN, BSN, MPH Author
MULTIPLE SCLEROSIS Mary Beth Rensberger, RN, BSN, MPH Author All rights reserved. Purchasers of this module are permitted to reproduce the forms contained herein for their individual internal use only.
Understanding your Tecfidera treatment
Understanding your Tecfidera treatment Information for patients who have been prescribed treatment with Tecfidera. (dimethyl fumarate) Contents About Multiple Sclerosis (MS) What is MS? Symptoms of MS
Understanding your Tecfidera treatment
Understanding your Tecfidera treatment Information for patients who have been prescribed treatment with Tecfidera. (dimethyl fumarate) Contents About Multiple Sclerosis (MS) What is MS? Symptoms of MS
AUBMC Multiple Sclerosis Center
AUBMC Multiple Sclerosis Center 1 AUBMC Multiple Sclerosis Center The vision of the American University of Beirut Medical Center (AUBMC) is to be the leading academic medical center in Lebanon and the
Accuracy in Space and Time: Diagnosing Multiple Sclerosis. 2012 Genzyme Corporation, a Sanofi company.
Accuracy in Space and Time: Diagnosing Multiple Sclerosis 2012 Genzyme Corporation, a Sanofi company. Brought All rights to reserved. you by www.msatrium.com, MS.US.PO876.1012 your gateway to MS knowledge.
Webinar title: Know Your Options for Treating Severe Spasticity
Webinar title: Know Your Options for Treating Severe Spasticity Presented by: Dr. Gerald Bilsky, Physiatrist Medical Director of Outpatient Services and Associate Medical Director of Acquired Brain Injury
Relationship between fatigue, cognitive dysfunction and small fiber neuropathy. Elske Hoitsma
Relationship between fatigue, cognitive dysfunction and small fiber neuropathy Elske Hoitsma Typical patient 45 year old male, Runs his own busy company, married, 4 young kids. Has always been very energetic
Multiple Sclerosis. Matt Hulvey BL A - 615
Multiple Sclerosis Matt Hulvey BL A - 615 Multiple Sclerosis Multiple Sclerosis (MS) is an idiopathic inflammatory disease of the central nervous system (CNS) MS is characterized by demyelination (lesions)
Many people with MS use some form of conventional medical treatment, and many people also use complementary and alternative medicine (CAM).
Complementary and alternative medicine (CAM) CAM therapies can generally be divided into the following categories: Biologically based therapies (eg, dietary supplements, diets, bee venom therapy, hyperbaric
Management in the pre-hospital setting
Management in the pre-hospital setting Inflammation of the joints Two main types: Osteoarthritis - cartilage loss from wear and tear Rheumatoid arthritis - autoimmune disorder Affects all age groups,
CAMBRIDGE UNIVERSITY CENTRE FOR BRAIN REPAIR A layman's account of our scientific objectives What is Brain Damage? Many forms of trauma and disease affect the nervous system to produce permanent neurological
Optic Neuritis. The optic nerve fibers are coated with myelin to help them conduct the electrical signals back to your brain.
Optic Neuritis Your doctor thinks that you have had an episode of optic neuritis. This is the most common cause of sudden visual loss in a young patient. It is often associated with discomfort in or around
Understanding How Existing and Emerging MS Therapies Work
Understanding How Existing and Emerging MS Therapies Work This is a promising and hopeful time in the field of multiple sclerosis (MS). Many new and different therapies are nearing the final stages of
Clinical features. Chapter 2. Clinical manifestations. Course
Chapter 2 Clinical features Clinical manifestations The wide range of symptoms and signs of multiple sclerosis (MS) reflect multifocal lesions in the central nervous system (CNS), including in the afferent
Multiple Sclerosis & MS Ireland Media Fact Sheet
Multiple Sclerosis & MS Ireland Media Fact Sheet This fact sheets gives a summary of the main facts and issues relating to Multiple Sclerosis and gives an overview of the services offered by MS Ireland.
New perception of disability including cognition, fatigue, pain and other impairments related to MS
New perception of disability including cognition, fatigue, pain and other impairments related to MS Diego Cadavid, MD Director, MS Clinical Development Biogen Idec 1 Need for clarity on terminology for
Spine Care Centre (SCC) protocols for Multiple Sclerosis Update 1 August 2015
Spine Care Centre (SCC) protocols for Multiple Sclerosis Update 1 August 2015 Introduction Multiple sclerosis (MS) affects nerves in the brain and spinal cord, causing a wide range of symptoms including
06/06/2012. The Impact of Multiple Sclerosis in the Pacific Northwest. James Bowen, MD. Swedish Neuroscience Institute
The Impact of Multiple Sclerosis in the Pacific Northwest James Bowen, MD Multiple Sclerosis Center Multiple Sclerosis Center Swedish Neuroscience Institute 1 2 Motor Symptoms of MS Weakness Spasticity
Summary HTA. Interferons and Natalizumab for Multiple Sclerosis Clar C, Velasco-Garrido M, Gericke C. HTA-Report Summary
Summary HTA HTA-Report Summary Interferons and Natalizumab for Multiple Sclerosis Clar C, Velasco-Garrido M, Gericke C Health policy background Multiple sclerosis (MS) is a chronic inflammatory disease
MULTIPLE SCLEROSIS. Megan Snyder INTRODUCTION TO EPIDEMOLOGY
MULTIPLE SCLEROSIS Megan Snyder INTRODUCTION TO EPIDEMOLOGY Snyder 1 Personal Connection to Multiple Sclerosis Multiple sclerosis (MS) is an extremely painful disease of which not enough is understood.
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Daclizumab for treating relapsing-remitting multiple Draft scope (pre-referral) Draft remit/appraisal objective To
There's no cure for multiple sclerosis. However treatments can help treat attacks, modify the course of the disease and treat symptoms.
MayoClinic.com reprints This single copy is for your personal, noncommercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, use the reprints
OHTAC Recommendation
OHTAC Recommendation Multiple Sclerosis and Chronic Cerebrospinal Venous Insufficiency Presented to the Ontario Health Technology Advisory Committee in May 2010 May 2010 Issue Background A review on the
Clinically isolated syndrome (CIS)
Clinically isolated syndrome (CIS) Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 We hope you find the information in this factsheet helpful. If you would
IF YOU ARE RECEIVING TREATMENT WITH TYSABRI FOR RELAPSING-REMITTING MS (NATALIZUMAB)
IF YOU ARE RECEIVING (NATALIZUMAB) TREATMENT WITH TYSABRI FOR RELAPSING-REMITTING MS Read the patient information leaflet that accompanies the medicine carefully. 1 This brochure is a supplement to the
Vision Health: Conditions, Disorders & Treatments NEUROOPTHALMOLOGY
Vision Health: Conditions, Disorders & Treatments NEUROOPTHALMOLOGY Neuroophthalmology focuses on conditions caused by brain or systemic abnormalities that result in visual disturbances, among other symptoms.
Multiple Sclerosis (MS) is a disease of the central nervous system (including the brain and spinal cord) in which the nerves degenerate.
What is Multiple Sclerosis? Multiple Sclerosis (MS) is a disease of the central nervous system (including the brain and spinal cord) in which the nerves degenerate. A disease of the central nervous system
Supporting MS-Related Disability Claims to Private Insurers: The Physician s Role
Supporting MS-Related Disability Claims to Private Insurers: The Physician s Role What Is This Guide? This guide was compiled by the National Multiple Sclerosis Society as an aid to health care professionals
Progress in MS: Current and Emerging Therapies
Progress in MS: Current and Emerging Therapies Presented by: Dr. Kathryn Giles, MD MSc FRCPC The MS Society gratefully acknowledges the grant received from Biogen Idec Canada, which makes possible the
FastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
The Nuts and Bolts of Multiple Sclerosis. Rebecca Milholland, M.D., Ph.D. Center for Neurosciences
The Nuts and Bolts of Multiple Sclerosis Rebecca Milholland, M.D., Ph.D. Center for Neurosciences Objectives Discuss which patients are at risk for Multiple Sclerosis Discuss the diagnostic criteria for
Multiple Sclerosis Society of Canada. CADA Presentation May 4, 2011
Multiple Sclerosis Society of Canada CADA Presentation May 4, 2011 1 MS Society s Mission To be a leader in finding a cure for multiple sclerosis and enabling people affected by MS to enhance their quality
NEW DIRECTION IN THE IMPROVEMENT OF CLINICAL CONDITIONS IN MULTIPLE SCLEROSIS PATIENTS By F. De Silvestri, E. Romani, A. Grasso
NEW DIRECTION IN THE IMPROVEMENT OF CLINICAL CONDITIONS IN MULTIPLE SCLEROSIS PATIENTS By F. De Silvestri, E. Romani, A. Grasso Introduction Multiple sclerosis (MS), in its many and varied clinical forms,
2.1 Who first described NMO?
History & Discovery 54 2 History & Discovery 2.1 Who first described NMO? 2.2 What is the difference between NMO and Multiple Sclerosis? 2.3 How common is NMO? 2.4 Who is affected by NMO? 2.1 Who first
Welcome to the Medical Risk Webinar: a taster of Assessing and Managing Medical Risk for Insurers courses. 26 April 2013
Welcome to the Medical Risk Webinar: a taster of Assessing and Managing Medical Risk for Insurers courses 26 April 2013 1 Parkinson s Disease & Multiple Sclerosis Dr Nick Niven Jenkins 2 Movement Human
Cerebral Palsy. In order to function, the brain needs a continuous supply of oxygen.
Cerebral Palsy Introduction Cerebral palsy, or CP, can cause serious neurological symptoms in children. Up to 5000 children in the United States are diagnosed with cerebral palsy every year. This reference
AUBAGIO (teriflunomide) oral tablet
AUBAGIO (teriflunomide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
CNS DEMYLINATING DISORDERS
CNS DEMYLINATING DISORDERS Multiple sclerosis A Dutch saint named Lidwina, who died in 1433, may have been one of the first known MS patients. After she fell while ice skating, she developed symptoms such
Cerebral Palsy. 1995-2014, The Patient Education Institute, Inc. www.x-plain.com nr200105 Last reviewed: 06/17/2014 1
Cerebral Palsy Introduction Cerebral palsy, or CP, can cause serious neurological symptoms in children. Thousands of children are diagnosed with cerebral palsy every year. This reference summary explains
Massage Therapy & Multiple Sclerosis
Massage Therapy & Multiple Sclerosis National Massage Therapy Awareness Week October 2008 Presented by the Massage Therapist Association of Saskatchewan, Inc. MTAS Inc., 2008 Researched & written by Cynthia
A blood sample will be collected annually for up to 2 years for JCV antibody testing.
Mellen Center Currently Enrolling Non-Treatment Trials STRATIFY-2 JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri Primary Investigator:
THE SPINAL CORD AND THE INFLUENCE OF ITS DAMAGE ON THE HUMAN BODY
THE SPINAL CORD AND THE INFLUENCE OF ITS DAMAGE ON THE HUMAN BODY THE SPINAL CORD. A part of the Central Nervous System The nervous system is a vast network of cells, which carry information in the form
About MS. An introduction to. An introduction to multiple sclerosis for people who have recently been diagnosed. What is MS? Is it common?
An introduction to multiple sclerosis for people who have recently been diagnosed When you have just been diagnosed with multiple sclerosis, you will probably have many questions about the condition and
Multifocal Motor Neuropathy. Jonathan Katz, MD Richard Lewis, MD
Multifocal Motor Neuropathy Jonathan Katz, MD Richard Lewis, MD What is Multifocal Motor Neuropathy? Multifocal Motor Neuropathy (MMN) is a rare condition in which multiple motor nerves are attacked by
Multiple Sclerosis Ireland, September 2013. Contents Summary 2 Commentary 3 Recommendations 5 Information on MS 6 Personal testimonies 9
Submission to the Department of Health Consultation on Draft Misuse of Drugs (Amendment) Regulations 2013 which will amend the Misuse of Drugs Regulations, 1988 Multiple Sclerosis Ireland, September 2013
MULTIPLE SCLEROSIS NURSING INTERNATIONAL CERTIFICATION EXAMINATION
MULTIPLE SCLEROSIS NURSING INTERNATIONAL CERTIFICATION EXAMINATION HANDBOOK FOR CANDIDATES 2016 TESTING PERIODS Conference Testing CMSC Annual Meeting in National Harbor, MD Only Application Deadline:
The Prospect of Stem Cell Therapy in Multiple Sclerosis. Multiple sclerosis is a multifocal inflammatory disease of the central
The Prospect of Stem Cell Therapy in Multiple Sclerosis Multiple sclerosis is a multifocal inflammatory disease of the central nervous system that generally affects young individuals, causing paralysis
Treatment of Dysarthria in Patients with Multiple Sclerosis. Barbara Bryant Jane Vyce
Treatment of Dysarthria in Patients with Multiple Sclerosis Barbara Bryant Jane Vyce What is MS? An autoimmune disease Destruction of myelin Destruction of axons What is MS? Etiology/Pathophysiology Cause
ALL ABOUT SPASTICITY. www.almirall.com. Solutions with you in mind
ALL ABOUT SPASTICITY www.almirall.com Solutions with you in mind WHAT IS SPASTICITY? The muscles of the body maintain what is called normal muscle tone, a level of muscle tension that allows us to hold
Neurofibromatosis Type 2: Information for Patients & Families by Mia MacCollin, M.D., Catherine Bove, R.N. Ed. & M. Priscilla Short, M.D.
Neurofibromatosis Type 2: Information for Patients & Families by Mia MacCollin, M.D., Catherine Bove, R.N. Ed. & M. Priscilla Short, M.D. Neurofibromatosis Type 2 is a rare genetic disease, which causes
A Letter From the MS Coalition
0 A Letter From the MS Coalition The treatment of multiple sclerosis (MS) requires a comprehensive management strategy. One important component of that strategy is modifying the disease course. When deciding
Roche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA
Media Release Basel, 28 June 2016 Roche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA OCREVUS is the first investigational medicine
Stepping toward a different treatment option LEARN WHAT ACTHAR CAN DO FOR YOU
FOR MS RELAPSES Stepping toward a different treatment option LEARN WHAT ACTHAR CAN DO FOR YOU As a person with multiple sclerosis (MS), you know firsthand the profound impact MS relapses can have on your
Transverse Myelitis ISBN 978-1-901893-57-1. A guide for patients and carers
Transverse Myelitis ISBN 978-1-901893-57-1 A guide for patients and carers The Brain and Spine Foundation provides support and information on all aspects of neurological conditions. Our publications are
Biogen Idec Contacts: Media: Amy Brockelman (617) 914-6524 Investor: Eric Hoffman (617) 679-2812
NEWS RELEASE Media: Nikki Levy (650) 225-1729 Investor: Susan Morris (650) 225-6523 Biogen Idec Contacts: Media: Amy Brockelman (617) 914-6524 Investor: Eric Hoffman (617) 679-2812 GENENTECH AND BIOGEN
Media Release. Basel, 8 October 2015
Media Release Basel, 8 October 2015 Roche s ocrelizumab first investigational medicine to show positive pivotal study results in both relapsing and primary progressive forms of multiple sclerosis Ocrelizumab
GLOBAL SURVEY FACT SHEET
Multiple sclerosis (MS) is a chronic, often disabling, disease that attacks the central nervous system, which is made up of the brain, spinal cord, and optic nerves. Symptoms may be mild or severe, ranging
Autoimmunity. Autoimmunity. Genetic Contributions to Autoimmunity. Targets of Autoimmunity
Autoimmunity Factors predisposing an individual to autoimmune disease Mechanisms of initiation of autoimmunity Pathogenesis of particular autoimmune disease Animal models of autoimmune disease Treatment
Acute Low Back Pain. North American Spine Society Public Education Series
Acute Low Back Pain North American Spine Society Public Education Series What Is Acute Low Back Pain? Acute low back pain (LBP) is defined as low back pain present for up to six weeks. It may be experienced
1: Motor neurone disease (MND)
1: Motor neurone disease (MND) This section provides basic facts about motor neurone disease (MND) and its diagnosis. The following information is an extracted section from our full guide Living with motor
F r e q u e n t l y A s k e d Q u e s t i o n s
Myasthenia Gravis Q: What is myasthenia gravis (MG)? A: Myasthenia gravis (meye-uhss- THEEN-ee-uh GRAV uhss) (MG) is an autoimmune disease that weakens the muscles. The name comes from Greek and Latin
GENENTECH S OCRELIZUMAB FIRST INVESTIGATIONAL MEDICINE TO SHOW EFFICACY IN PEOPLE WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS IN LARGE PHASE III STUDY
NEWS RELEASE Media Contact: Tara Iannuccillo (650) 467-6800 Investor Contacts: Stefan Foser Karl Mahler (650) 467-2016 011 41 61 687 8503 GENENTECH S OCRELIZUMAB FIRST INVESTIGATIONAL MEDICINE TO SHOW
PARKINSON S DISEASE IN LONG-TERM-CARE SETTINGS
PARKINSON S DISEASE IN LONG-TERM-CARE SETTINGS De Anna Looper, RN CHPN Corporate Clinical Consultant / Legal Nurse Consultant Carrefour Associates L.L.C. PARKINSON S DISEASE IN LONG-TERM-CARE SETTINGS
The rising cost of prescription drugs to treat multiple sclerosis in upstate New York
T H E F A C T S A B O U T The rising cost of prescription drugs to treat multiple sclerosis in upstate New York Per-person mean annual prescription drug cost to treat multiple sclerosis Annual drug cost
NEW PATIENT CLINICAL INFORMATION FORM. Booth Gardner Parkinson s Care & Movement Disorders Center Evergreen Neuroscience Institute
NEW PATIENT CLINICAL INFORMATION FORM Booth Gardner Parkinson s Care & Movement Disorders Center Evergreen Neuroscience Institute Date: Name: Referring Doctor: How did you hear about us? NWPF Your Physician:
Chronic Low Back Pain
Chronic Low Back Pain North American Spine Society Public Education Series What is Chronic Pain? Low back pain is considered to be chronic if it has been present for longer than three months. Chronic low
A Genetic Analysis of Rheumatoid Arthritis
A Genetic Analysis of Rheumatoid Arthritis Introduction to Rheumatoid Arthritis: Classification and Diagnosis Rheumatoid arthritis is a chronic inflammatory disorder that affects mainly synovial joints.
ARTICLE #1 PLEASE RETURN AT THE END OF THE HOUR
ARTICLE #1 PLEASE RETURN AT THE END OF THE HOUR Alcoholism By Mayo Clinic staff Original Article: http://www.mayoclinic.com/health/alcoholism/ds00340 Definition Alcoholism is a chronic and often progressive
